Dupilumab is generally well tolerated and improves health-related quality of life associated with rhinoconjunctivitis in patients with uncontrolled moderate to severe asthma with comorbid allergic rhinitis, according to study findings presented at AAAAI 2019.
“Dupilumab, a fully human, VelocImmune-derived anti-interleukin (IL)-4R? mAb [monoclonal antibody] that inhibits signaling of IL-4/IL-13, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis,” the researchers explained.
The findings were part of the phase 3 LIBERTY ASTHMA QUEST study that evaluated the quality of life in patients with moderate to severe asthma patients’ following dupilumab treatment. Patients with asthma (?12 years) and self-reported comorbid allergic rhinitis were included in the study, and each patient completed the Standardized Rhinoconjunctivitis Quality of Life Questionnaire. Participants were on medium- to high-dose inhaled corticosteroids (ICS) and ?2 additional controllers.
